Hormone Receptor

Hormones are chemical messengers that travel through the bloodstream, but they cannot simply enter every cell they encounter. They communicate through receptors — specialized proteins that recognize and bind a specific hormone, much like a lock and key. When a hormone docks onto its matching receptor, it triggers a cascade of changes inside the cell: genes may be switched on or off, proteins may be produced or suppressed, and the cell's behavior may shift dramatically. Without the receptor, the hormone passes by without effect.

In breast cancer, the most clinically important hormone receptors are the estrogen receptor (ER) and the progesterone receptor (PR). A tumor is called ER-positive if a significant percentage of its cells contain estrogen receptors, and PR-positive if they contain progesterone receptors. Tumors that test positive for either or both are collectively called hormone receptor–positive, or HR-positive. About 70 to 80 percent of breast cancers are HR-positive, making this the most common breast cancer subtype.

HR-positive tumors rely on estrogen (and to a lesser extent progesterone) as a growth signal. This dependency is actually an advantage therapeutically, because it means the tumor has an identifiable vulnerability. Treatments that block hormone receptors or reduce hormone production — including tamoxifen, aromatase inhibitors, and ovarian suppression — deprive the tumor of its fuel. These hormone therapies are typically taken for five to ten years and substantially reduce the risk of recurrence. Tumors that are HR-negative do not respond to hormone therapy and require different treatment strategies.

Hormone receptor status is one of the first and most consequential pieces of information you receive after a breast cancer diagnosis. It does not just describe the cancer — it points directly toward treatment. Knowing your tumor is hormone receptor–positive means a whole class of effective, generally well-tolerated therapies is available to you, and that you will likely be recommended to take one for several years after surgery and initial treatment to reduce the chance of the cancer returning.

It also provides context for understanding your prognosis. HR-positive breast cancers tend to be slower-growing than hormone receptor–negative cancers and often have very favorable long-term outcomes, particularly when detected early. At the same time, HR-positive cancers can recur years or even decades after initial treatment — which is why the extended duration of hormone therapy (five to ten years, or sometimes longer) is recommended for many patients. Understanding the reasoning behind that recommendation can make it easier to stay committed to a treatment plan that extends well beyond the acute phase of your care.